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Thirty years after its discovery, the hepatitis E virus (HEV) continues to represent a major public
health problem in developing countries. In developed countries, it has emerged as a significant
cause of non-travel-associated acute hepatitis. HEV infects a wide range of mammalian species
and a key reservoir worldwide appears to be swine. Genomic sequence similarity between some
human HEV genotypes and swine HEV strains has been identified and we know that humans can
acquire HEV infection from animals. Although for the most part the clinical course of HEV
infection is asymptomatic or mild, significant risk of serious disease exists in pregnant women
and those with chronic liver disease. In addition, there are data on the threat of chronic
infections in immunocompromised patients. Beyond management of exposure by public health
measures, recent data support that active immunisation can prevent hepatitis E, highlighting the
need for vaccination programmes. Here we review the current knowledge on HEV, its
epidemiology, and the management and prevention of human disease.
Introduction
First recognised in Asia almost 30 years ago as the main cause
of non-A, non-B enterically transmitted hepatitis,
1,2 hepati-
tis E virus (HEV) is now acknowledged to have worldwide
distribution.
In countries with poor sanitation, HEV is endemic and
typically causes explosive outbreaks of acute hepatitis,
usually associated with faecal contamination of the water
supply. The disease is generally mild, yet pregnant women
suffer significant morbidity and mortality.
3–5
In contrast, in countries with high standards of sanitation,
hepatitis E occurs sporadically, initially identified as an
imported disease in travellers from highly endemic regions,
but subsequently diagnosed in patients with no travel
history as well; this latter form has been named ‘hepatitis E
indigenous to developed countries’.
6–26
Phylogenetic analysis of HEV genome from different
isolates has led to the identification of four main genotypes,
with genotypes 1 and 2 circulating in Africa and Asia,
genotype 3 showing a broad distribution worldwide, and
genotype 4 being restricted to Asia.
Genotypes 3 and 4 are enzootic in a variety of wild and
domestic animals, particularly pigs,
8,27–36 which gave rise to
the question of whether human HEV infection is a zoonosis?
Evidence from Japan
37–40 and China
28 now confirms that
humans can acquire HEV infection from animals.
Hepatitis E represents a significant public health and
economic burden particularly in countries where the
absence of sanitation infrastructures, or their breakdown as
a consequence of wars or natural disasters, brings the
hygienic conditions below a safe level.
4,41,42 The develop-
ment of an effective vaccine is expected to dramatically
reduce the incidence of the disease, particularly in the most
susceptible individuals such as pregnant women.
Virology
Taxonomy and virus structure
In the early 1980s, the observation that individuals involved
in epidemics of jaundice were seronegative for markers of
acute hepatitis A and B suggested the existence of an
unrecognised aetiological agent of enterically transmitted
hepatitis.
1,2 The confirmation came in 1983, when small,
virus-like particles were identified by immune electron
microscopy in stool specimens from a volunteer experimen-
tally infected with pooled faecal extracts from human cases
of epidemic non-A, non-B hepatitis.
43 The pathogen, HEV, is
a non-enveloped virus, 27–30nm in diameter, with an
icosahedral capsid. In the early 1990s, the virus genome
was cloned
44,45 and diagnostic antibody assays were devel-
oped.
46 After being provisionally assigned to the Caliciviridae
family,
47 HEV was re-classified as the sole member of the
genus Hepevirus, family Hepeviridae, in 2004.
48
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The HEV genome consists of a single-stranded RNA molecule
with positive polarity approximately 7300 nucleotides in
length.
45,49,50 It comprises a short 50 noncoding region (28
nucleotides), followed by three open reading frames (ORF), a
30 noncoding region (65–74 nucleotides), and a poly(A) tail
(Figure 1).
45,53 The genome is capped at its 50 terminus
54 and
capping is required for virus viability.
55
ORF1 (approximately 5kb) encodes a large nonstructural
polyprotein with key functions for viral genome replication
and viral protein processing. ORF2 (approximately 2kb)
occupies the 30 end of the coding region and encodes the
capsid protein.
45,51,56–58 The N-terminal region of ORF2
protein binds the 50 noncoding region of the HEV genome
59
and is possibly involved in viral encapsidation.
41 Only the
ORF2 recombinant protein truncated at its N-termini can
efficiently self-assemble in vitro into empty, virus-like
particles. These share antigenic properties with the native
HEV capsid protein, although they are smaller than the
native virions.
57,58
ORF3 is a small reading frame (372 bases) with the 50 end
overlapping ORF1 by four nucleotides and the 30 end
overlapping ORF2 by 331 nucleotides;
45,53,51 it encodes a
small phosphoprotein that associates with the cytoskeleton
and the capsid protein.
60,61 The product of ORF3 is possibly
involved in modulation of cell signalling
62,63 and in the
assembly of the HEV nucleocapsid;
60 recently, it has been
shown that this protein is essential for infectivity in vivo
64
but not in vitro.
65 The poly(A) tail is necessary for binding of
RNA-dependent RNA polymerase (RdRp) to the 30 noncoding
region.
41,66
Compared with genotypes 1–3, the genome of genotype 4
contains a nucleotide insertion (U) just after the second AUG
codon of ORF3, which changes the downstream reading
frames so that, for genotype 4, different AUG codons were
initially expected to initiate translation in both ORF2 and
ORF3.
52,53 However, a recent study by Graff et al.,
51 using a
replicon, demonstrated that ORF2 and ORF3 proteins are
produced from a single subgenomic RNA of approximately
2.2kb, which initiates downstream of the first two AUG
codons of ORF3 in genotypes 1–3 (downstream of the
insertion of U in genotype 4), using two closely spaced start
codons. It is therefore expected that both ORF2 and ORF3
proteins are similar in size in all four genotypes.
51
Resistance to physical and chemical agents
Boiling and chlorination of water represent the main
measures to control and prevent infection. However, Emer-
son et al.
67 reported that HEV is moderately resistant to heat
inactivation. This finding was further corroborated in a more
recent study that showed how HEV was still infectious on
incubation at 561C for 30min.
68
HEV genetic diversity
Comparative nucleotide sequence analysis of whole gen-
omes of HEV isolates has revealed extensive genomic
diversity leading to the identification of four major geno-
types and several subtypes within each genotype (Figure 2).
However, although the separation of HEV into four major
genogroups is widely accepted, so far there is no agreement
about the number of subtypes within each genotype.
69
Genomic regions that have been used for phylogenetic
purposes include a 301-nucleotide-long sequence at the 50
end of the ORF2 region (Figure 2)
69 and a 306-nucleotide-
long sequence in the RdRp of ORF1.
70
Replication in cell culture
The lack of efficient cell culture systems has hampered
detailed studies on HEV biology, critical for helping to
develop diagnostic assays and vaccine research.
68 Replication
and propagation of HEV was attempted with limited success
by using continuous cell lines
71,72 and primary hepatocytes
from nonhuman primates.
73 Recently, more efficient
cell-culture systems were developed in cell lines,
67,68,74
allowing studies on HEV thermal stability and improving
neutralisation tests. It was shown that anti-HEV antibodies
are broadly crossreactive because HEV genotype 3 was
neutralised by convalescent serum samples from patients
Subgenomic RNA 
(approximately 2.2 kb)
ORF 3
ORF 2
Poly(A)
tail
Poly(A)
tail
Cap
Genomic RNA (approximately 7.3kb)
Cap
ORF1 Met Pr P Hel RdRp YX
Figure 1 Schematic organisation of genomic and subgenomic HEV RNAs. ORF1 encodes a nonstructural polyprotein; ORF2 encodes the capsid protein; ORF3
encodes a phosphoprotein. Met, methyltransferase; Y, no function assigned at present; Pr, putative papain-like cysteine protease; P, proline ‘hinge’; X, no function
assigned at present; Hel, RNA helicase; RdRp, RNA-dependent RNA polymerase.
51,52
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68 Similarly,
genotype 1 was neutralised by convalescent serum samples
obtained from rhesus monkey infected with any of the four
mammalian genotypes.
74 In addition, serum specimens
obtained 24 years after the onset of HEV infection could
prevent the propagation of HEV in cell culture, suggesting
that long-lasting HEV antibodies with neutralisation activity
are induced.
68
Epidemiology
Geographical distribution of HEV according to
genotype
The geographical distribution of HEV genotypes is complex
and continuously evolving (Figure 3). Genotype 1 exten-
sively circulates in Asia (including India,
75–78 Pakistan,
79
Nepal,
80,81 Bangladesh,
82 China,
49,83–85 Kyrgyzstan,
86 and
Uzbekistan
87) and Africa (including Egypt,
88 Algeria,
89
Morocco,
87 Namibia,
90 Sudan,
91 and Chad
91,92), whereas
genotype 2 has been isolated only in Mexico
93 and in
some African countries (Nigeria,
94 Namibia,
95 Chad,
91 and
Sudan
91). Genotype 3 has been detected worldwide (Amer-
ica,
13,26,32,33,96–99 Europe,
9,10,12,15,16,18,20,21,27,34,35,100–102
Asia,
25,33,37,39,40,103–111 Australia,
69 and New Zealand
11) with
the exception of Africa, whereas genotype 4 is restricted to
India
112,113 and East Asia.
39,84,103,114–118
Although genotypes 1 and 2 are considered human viruses,
genotypes 3 and 4 have been isolated from both hu-
mans
10,11,16,17,20,25,97,119–122 and animals.
32,33,123–126 Of sig-
nificant interest is the unique distribution of HEV
isolates in India, as human and swine HEVs belong to
different genotypes (genotype 1 and genotype 4,
respectively);
113 genotype 4 appears to be specifically re-
stricted to swine and it has never been isolated from humans,
in spite of extensive investigations.
127,128 Phylo-
genetic analysis shows that the Indian HEV genotype 4
represents a distinct variant among HEV genotype 4 isolates
with 26 unique amino-acid substitutions (16 in ORF1, 8 in
ORF2, and 2 in ORF3).
129 Whether the difference in sequence,
particularly in ORF2, determines tropism and explains the
lack of infectivity in humans remains to be determined.
Mode of transmission
Waterborne
In developing countries, HEV is transmitted through the
faecal–oral route, mainly by the consumption of water
contaminated with sewage disposal.
130 In developed coun-
tries, HEV RNA has been detected in human sewage
only occasionally.
19,20 Interestingly, HEV rescued
from sewage in Spain was infectious for rhesus monkey,
131
raising the possibility that HEV might occasionally
Gt. 2
Gt. 1
Gt. 4
Gt. 3
4e
3a
1c
4a
1b
1a
1e
1d
4b
4c
4d
3b
3c
3e
3f
3d
Figure 2 Phylogeny of HEV genotypes (Gt.) based on the 301-nucleotide-long 50 end of the ORF2 region, the most conserved in all HEV isolates. Sequences
determined from this region accounted for the majority of HEV sequences.
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epidemic regions.
16,131,132
Foodborne
Evidence that food can transmit HEV came from Japan,
where acute hepatitis E was diagnosed in patients who
consumed raw or undercooked pig liver and intestine,
23 wild
boar meat and liver,
38,110,133 and deer meat
40 contaminated
with the virus. HEV with identical nucleotide sequence was
detected both in the blood of affected patients and in
batches of meat and liver not consumed.
40,109,133 A higher
HEV IgG seroprevalence in Japanese individuals with
frequent dietary consumption of raw deer meat, in compar-
ison with a control group, indirectly supports the foodborne
route.
134 Food as a vehicle of infection has not yet been
proven in other developed countries.
Person-to-person transmission
In contrast to hepatitis A virus (HAV) infection, secondary
transmission among household members of patients with
acute hepatitis E is an uncommon event,
135,136 both in the
context of outbreaks
137 and sporadic infections.
138,139
Parenteral transmission
HEV-infected individuals can transmit the infection by
donating blood during the viraemic period. Viraemia can
be detected even in asymptomatic infections and during the
incubation period,
140,141 even in the absence of aminotrans-
ferase elevation.
140 Transmission of HEV via blood transfu-
sion has been documented in several countries, including
Saudi Arabia,
142 Japan,
105,143,144 and the UK,
145 where
matching RNA sequences were found in blood donors and
their recipients.
Mother-to-child transmission
Mother-to-child transmission of HEV has been scarcely
documented; however, the available data suggest a signifi-
cant rate of HEV vertical transmission among the HEV RNA-
positive mothers with worsening liver disease.
146–149
Epidemic versus sporadic forms and seasonality
In the developing world, HEV infection represents the most
common aetiological agent of periodic outbreaks of acute
hepatitis.
42,130,136,150 Epidemics are most frequent during the
monsoon season when flooding causes faecal contamination
Gt 1
Gt 2
Gt 3
Gt 4
Gt 1 and 4 
Gt 1 and 2
Gt 3 and 4
Gt 1 and 3
Gt 2 and 3
Figure 3 Geographical distribution of HEV isolates according to genotypes (Gt). HEV Gt 1 and 2: epidemic strains causing human infection. HEV Gt 3 and 4:
zoonotic strains isolated from humans and a variety of animals, particularly pigs. In some countries, different genotypes co-circulate in distinct ecological niches: Gt 1
and 4 in China, India, and Vietnam; Gt 1 and 2 in several African countries, including Namibia, Chad, and Sudan; Gt 3 and 4 in Japan; Gt 1 and 3 in Cambodia; Gt2
and 3 in Mexico.
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41 Between epidemics, HEV is transmitted
in a discrete manner leading to the onset of sporadic forms of
acute hepatitis. In India, 30–70% of all cases of acute
sporadic hepatitis are caused by HEV infection.
41,151
In economically developed regions, indigenous hepatitis E
is largely a sporadic disease. However, in Japan, small
outbreaks have been described as a consequence of con-
sumption of the same contaminated food.
152,153 A small
outbreak involving a family with two children has also been
reported in France.
139 No clear seasonality has been observed
in developed countries.
24,154
Age- and sex-specific clinical attack rates and case
fatality rates
Clinical infection concentrates among adolescents and
young adults in countries of high endemicity. During
outbreaks, the clinical attack rate (3–30%)
136,150,155–157 is
highest among pregnant women.
4,158,159 The mortality rate,
which is usually low (0.07–0.6%),
136,150,160,161 can reach
values as high as 25–31% in pregnant women, particularly
during the third trimester of pregnancy.
4,136,150,155,162–164
A distinct characteristic of hepatitis E indigenous to
developed countries is its high attack rate among older
male adults.
13,26,100 This has been observed in both
Europe
10,16,18,20,100,101 and Japan,
24 which experienced the
greatest number of detected cases. No documented case of
hepatitis E has been identified in pregnant women in this
different epidemiological setting.
A high mortality, ranging between 25 and 70%, has been
recently documented among patients already suffering from
chronic liver disease of different aetiologies. These observa-
tions were made both in highly endemic countries, such as
India,
165–168 Pakistan,
169 and Nepal,
170 where hepatitis E is
caused by genotype 1, and in Europe,
171 where indigenous
hepatitis E is linked to genotype 3.
Seroprevalence of HEV infection
HEV seroprevalence studies have been conducted using
several antibody assays based on different recombinant
antigens, which do not always include the most relevant B-
cell epitopes, leading to lack of sensitivity and poor
reciprocal concordance.
172 In particular, a greater sensitivity
of currently available antibody assays has been reported in
detecting overt disease in comparison with subclinical
infections,
173 which may hamper seroepidemiological
investigations. Antibody assays based on the ORF2
protein, which exposes at least one major crossreactive
epitope shared by all HEV genotypes,
56,62,174 should be
used for investigating seroepidemiology
46,56,175,176 (see
‘Diagnosis’).
Seroprevalence studies in HEV epidemic countries, such as
India, have revealed that HEV infection is rare in children,
reaching peak prevalence (33–40%) only in early adult-
hood.
177 These data are in striking contrast with HAV
serosurveys, showing anti-HAV antibodies in the majority
of children by the age of three years.
177 The reason for the
difference in age-specific seroprevalence between HAV and
HEV, both transmitted by the faecal–oral route, remains
unanswered.
In contrast, HEV seroepidemiology closely mirrors that of
HAV in Egypt, a country highly endemic for HEV infection
(similar to India), where anti-HEV antibodies are detectable
in 65% of children younger than 10 years.
178 Although the
reason for the earlier exposure in life in Egypt remains
unknown, the widespread immunity of the population at an
early age might account for the absence of large outbreaks of
hepatitis E in the general population
179 and among pregnant
women.
180
In rural southern China, where the majority of HEV
infections are zoonotic (genotype 4), anti-HEV IgG is rarely
detected in children, rapidly increases in young adults, and
peaks (60–80%) at the age of 60 years.
181 Interestingly, after
30 years of age, but not in younger age groups, the
seroprevalence is two times higher for men than for women,
suggesting a link with different social roles adopted by men
and women once families are established.
181
Seroprevalence investigations in developed regions have
revealed the ubiquitous presence of anti-HEV antibodies
in the analysed populations, although with significant
differences between and within countries.
11,172,182–186 A
significant concern is the high seroprevalence among US
blood donors (18–21%)
184,187 compared with individuals
professionally exposed to swine HEV, such as veterinarians
(23–26%).
184
Some studies have documented an increasing seropreva-
lence with age in both sexes, suggesting a continuous
ongoing exposure to HEV.
172,182,187,188 In Japan, age-specific
profiles of anti-HEV and anti-HAV antibodies suggest silent
HEV infection in the last few decades, during which HAV
infection rates declined.
188
Zoonosis and host range
The possibility that HEV infection can be a zoonosis was
raised when a virus, closely related to the HEV human
strains, was isolated from pigs, initially in the USA
189 and,
subsequently, worldwide.
28,32–36,96,112,183,190–193
Experimental cross-species infections between swine and
primates have shown that swine HEV could infect primates
(surrogates for human infection), and the US-2 strain of
human HEV (genotype 3) could infect specific pathogen-free
pigs.
194 In contrast, US pigs could not support replication of
human epidemic strains (genotypes 1 and 2).
195 Similarly,
Indian pigs could be infected with swine HEV (genotype 4)
but not with human HEV (genotype 1).
112
These findings are supported by phylogenetic analysis data
showing a high degree of nucleotide and amino-acid
sequence homology between swine and human HEV isolates
of genotypes 3 and 4 from the same geographical regions,
suggesting that pigs may act as a reservoir for human
infection.
69,35,109,115,116,125 On the contrary, swine HEV
strains are highly divergent from the human strains of HEV
classified within genotypes 1 and 2.
69
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196 and develop a
self-limiting subclinical infection
189,197,198 with transient
viraemia (one to two weeks) but prolonged viral shedding
(three to four weeks) in faeces. Current pig-raising practices
perpetuate exposure of pigs to their waste, promoting viral
transmission.
196
Seroprevalence studies in pigs have shown the presence of
HEV IgG in an unexpectedly high proportion of ani-
mals,
36,199–201 with peaks up to 85% in the UK,
34 95–98%
in India,
127 and 70–100% in Japan.
109,202,203 Although pigs
are infected primarily at the early stage of production (1–3
months), HEV can still be detected by PCR at slaughter age,
meaning that swine HEV can enter the food chain.
28,36,98
This has been shown in Japan, where infectious HEV was
found in 2% of the pig liver packages ready for sale,
39 and
more recently in the USA
30 and in The Netherlands.
204 HEV
RNA was also detected in 3.1% of bile samples from swine in
abattoirs in eastern China.
28
HEV replicates in different visceral organs.
192,205,206 This
explains the common foodborne transmission in Japan
owing to the gastronomic habit of eating rarely, or poorly
cooked, pig liver and intestines. Despite absence of evidence
for HEV replication in muscles, HEV infection has been
transmitted by consumption of meat from boar and deer as
well.
38,40,133
The finding of infectious HEV in pig-farm manure slurry
samples
193 suggests that human exposure to swine waste
may represent an alternative mode of transmission of
zoonotic strains, particularly in regions where the water
supply comes from wells, rivers, and streams, and where
sewage treatment is not generally available.
181 In rural
eastern China, where 9.6% of pig herds were found to be
HEV RNA-positive by stool samples, a 74% higher risk of
infection among people professionally engaged in swine
farming was observed. Seroprevalence increased with the
duration of occupational exposure to swine.
28 There was also
a 29% higher risk of infection in people without occupa-
tional exposure to swine and residing in communities
downstream of the Chinese swine farms, compared with
those living in communities upstream.
28 Compared with
control individuals, increased HEV IgG seroprevalence was
also detected in people with occupational exposure to pigs in
other countries, including Sweden and The Nether-
lands.
183,207
Seroprevalence studies have shown that HEV natural
infection is widespread in many species of wild and domestic
mammals, including rats,
208–212 cattle,
115,209 goats,
127 wild
mongooses,
213 monkeys,
214 dogs,
215 and pet cats,
216 with
antibody positivity increasing with age in Japanese maca-
ques and Japanese domestic pet cats.
214,216 Although these
data show the prevalence of HEV circulation among animals,
they have not established the possible role of these animals
in transmitting HEV infection to humans. Of particular
interest is the high HEV seroprevalence among wild
rats,
208–212 as these rodents, ubiquitous worldwide, have
the potential to be infected with swine and human HEV
strains. Rats may therefore be an important intermediate
host between pigs and humans or, alternatively, a reservoir
for both human and swine infection.
The majority of studies on animals other than swine have
been more successful in detecting HEV antibodies than viral
RNA. Although HEV RNA from genotypes 3 and 4 has been
systematically found in pigs, boars, and deer, it has not yet
been defined with certainty which genotypes circulate
within other species. Two studies document HEV genotype
1 in horses
217 and pigs.
218 The finding of HEV genotype 1 in
rats
219 has subsequently been found to be a laboratory
error.
220 More studies are necessary to assess if HEV genotype
1 and 2 strains can induce sustainable infection in some
animal species. In view of the large number of animal species
that are potentially involved, further exploration of zoonotic
transmission of HEV is warranted.
23
HEV strains were identified in poultry as well as mammals;
phylogenetic analysis indicates that avian HEV is genetically
related to, but distinct from, mammalian HEV strains
221,222
and does not represent a risk for cross-infection to
humans.
Pathogenesis, immune response, and time course
of infection
It is thought that HEV infection initiates via cells lining
the alimentary tract (primary site of virus replication)
(Figure 4).
223 The virus then reaches the liver through the
portal vein
41 and replicates in the cytoplasm of hepatocytes
without causing direct cytolytic damage.
223 Several observa-
tions suggest that, in analogy with other hepatitis viruses,
liver injury is largely immune-mediated:
150,223,224 first,
viraemia precedes the onset of alanine transaminase eleva-
tion and liver histopathological changes;
225–227 secondly,
experimental infection of nonhuman primates has shown
how the liver damage coincides with the detection of serum
anti-HEV antibodies and with a decreasing level of HEV
antigens in the hepatocytes;
150,225 and finally, the lympho-
cytes infiltrating the liver have a cytotoxic/suppressor
immunophenotype.
150,225
HEV RNA is detectable in blood from as early as two weeks
before
173 and for two to four weeks after the onset of
symptoms.
228–230 HEV faecal excretion shows a similar
temporal pattern.
229 Once liver function has normalised,
HEV RNA is usually undetectable in blood and stool.
229
Viraemia and faecal shedding beyond the duration of
biochemical hepatitis are uncommon,
229–231 suggesting that
prolonged faecal shedding is not important in maintaining
the environmental reservoir of HEV.
229
The antibody responses are directed primarily against
epitopes in the ORF2 and ORF3 proteins and are typically
detectable at the onset of the disease, with IgM antibodies
persisting for two to six months.
223,228,232 Anti-HEV IgG
appears soon after IgM, and persists for a longer period of
time.
41,223,228,232,233 However, the possibility of repeated
infections being the cause of IgG persistence cannot be
excluded.
41
Hepatitis E Emerging Health Threats Journal
E Pelosi and I Clarke 2008, 1:e8
www.eht-journal.org page 6/17Overt disease in young adults is commonly the result of
primary infection.
234 The importance of antibodies in
protecting from clinical hepatitis E has been proven
experimentally in primates, in which passive immunisation
with anti-HEV antibodies was able to protect them against
overt disease after challenge with virulent HEV.
235
Limited data are available on anti-HEV cellular immune
response. Evidence for anti-HEV T-cell response was provided
by a study on patients with acute hepatitis E whose T-
lymphocytes showed sensitisation to HEV peptides.
236 The
same group was recently able to map CD4 T-cell epitopes in
the ORF2 and ORF3 proteins of HEV using lymphocyte
proliferation assays in patients with acute hepatitis E,
237
providing the basis for future studies on the immunopatho-
genesis of hepatitis E. No data are currently available
regarding anti-HEV-specific CD8 T-cell responses or the role
of cellular responses in the protection against viral infection.
Of great interest are the mechanisms determining the
severity of disease during pregnancy, in which fulminant
hepatitis is a common complication. HEV infection studied in
pregnant and nonpregnant healthy women has shown that
infection in pregnancy is associated with a shift in the Th cell
type 1/Th cell type 2 balance toward Th cell type 2 response.
238
However, at this time it is difficult to link the clinical severity
of the illness to this observation because the mechanism of
liver injury in HEV infection has not yet been clarified.
239 A
recent Indian study suggested that a subset of CD4-positive
interferon-g-secreting cells, which do not belong to either the
helper Th cell type 1 or type 2 phenotype, might be involved
in liver damage during acute HEV infection.
240
Clinical features
Acute infection
The incubation period ranges from two to 10 weeks with an
average of 40 days.
43,163,228 Hepatitis E is indistinguishable
from other forms of viral hepatitis. Typical clinical features
are one- to 10-day prodrome of malaise, fever, gastrointest-
inal symptoms (abdominal pain, anorexia, nausea, vomit-
ing), followed by the onset of jaundice.
41,150,155,161,241 Once
jaundice appears, prodromal symptoms subside. Clinical
jaundice is not a constant feature and anicteric forms of
hepatitis are well recognised.
242 Serum investigations reveal
raised levels of bilirubin (predominantly conjugated) and
alanine aminotransferase. The magnitude of the alanine
aminotransferase elevation does not correlate with the
severity of the liver injury, better expressed by the liver
synthetic function, as determined by coagulation function
estimation. Acute infection resolves in one to four weeks;
however, some patients develop a more prolonged clinical
illness with cholestasis (cholestatic hepatitis).
150 HEV infec-
tion is not known to progress to chronicity or cirrhosis
2,243
in immunocompetent patients.
Complications
A small proportion of patients develop fulminant or
subacute hepatic failure with high mortality as a result of
Months post-infection
Symptoms Convalescent period
HEV RNA in stool
HEV RNA in blood
ALT
Anti-HEV IgM
Anti-HEV IgG
Exposure to HEV
02 5 13 4
Figure 4 Time course of HEV infection and specific humoral immune response. This figure shows the correlation of HEV RNA in stool and blood, sign of liver
damage and development of anti-HEV antibody response with time. ALT, alanine aminotransferase; IgG, immunoglobulin G; IgM, immunoglobulin M.
150,153,173
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150,244,245 Fulminant hepatitis E has
been described worldwide but it is particularly common in
developing countries among pregnant women, mainly
during the third trimester.
164,239,246–249 In this setting, HEV
adversely affects both pregnant women and foetal outcome,
with high mortality rate, increased frequency of
abortions, preterm delivery, stillbirth, and neonatal
death.
23,99,148,150,239,250
In Japan, HEV genotype 4 appears to cause severe hepatitis
more frequently than genotype 3,
23,121,251 possibly as a
consequence of specific genomic mutations.
119 In Argentina,
a country not endemic for hepatitis E, fulminant hepatitis
has been recently diagnosed in three children infected with
HEV genotype 3.
99
Severe forms of hepatitis E have also been increasingly
documented among patients, mainly men, with stable
chronic liver disease of different aetiologies, including
chronic hepatitis B and C, autoimmune hepatitis, alcoholic
liver disease, cryptogenetic hepatitis, and Wilson’s
disease.
165–171,252,253
Prolonged mild hepatitis with viral shedding has been
described in immunocompromised patients during che-
motherapy for T-cell lymphoma.
143,254 More recently, the
evolution of HEV infection into chronic hepatitis E has been
reported in solid organ transplant patients in France:
255,256
they not only persistently shed the virus in the presence of
deranged alanine aminotransferase values, but also showed
histopathological changes similar to those observed in
chronic hepatitis C.
Uncommon HEV infection complications, described in
anecdotal reports, include the Guillain–Barre ´ syndrome,
257
acute transverse myelitis,
258 acute pancreatitis,
259 non-
immune haemolytic anaemia,
260 lymphocytic destructive
cholangitis,
261 and prolonged polyarthritis.
262
Asymptomatic infections
The number of asymptomatic infections far exceeds that of
icteric hepatitis, as a large proportion of individuals who test
positive for anti-HEV antibodies in highly endemic coun-
tries, such as India,
150 China,
28,181 and Egypt,
179 do not
recall having suffered from jaundice. Similar data, based
on seroprevalence, have been obtained from a variety of
population profiles in developed countries: blood donors
in Japan and the USA,
140,184 prisoners and drug users in
Denmark,
172 and individuals living in the community
in Spain.
182
Direct evidence of ongoing subclinical HEV infection in
the general population comes from a study conducted in
Honshu (Japan) on 6700 asymptomatic blood donors with
elevated aminotranferase levels during a three-year period:
about 3% of the individuals with an aminotransferase level
of X201IU/l (normal value o60IU/l) were HEV RNA-
positive.
140 Based on the number of asymptomatic viraemic
individuals and the incidence of clinical hepatitis E in
Honshu, the authors estimate that less than 0.1% of HEV-
infected cases exhibit clinical manifestation of the infec-
tion.
140 Asymptomatic viraemia has been detected in about
0.3% of individuals in rural eastern China.
28
Diagnosis
Antibody detection
HEVantibody assays represent the routine diagnostic tool for
acute hepatitis E cases. Test formats mostly consist of
indirect enzyme-linked immunosorbent assays (EIA),
with recombinant HEV proteins or peptides as detecting
antigens. Currently available commercial assays are based
mainly on HEV epidemic strains but EIA tests specific for
genotypes 3 and 4 have also been developed.
25,128,135
The specificity and sensitivity of these tests have not been
established with precision, limiting the reliability of labora-
tory results.
263
One of the most widely available commercial antibody
assays, the Genelabs-EIA, uses short recombinant proteins
derived from the 30 termini of ORF2 (42 amino acids) and
ORF3 (33 amino acids) from the Burmese (genotype 1) and
Mexican (genotype 2) prototype sequences.
263 However,
according to Zhou et al.,
175 a truncated form of the ORF2
protein, encompassing amino acids 112–607, contains the
neutralisation epitopes (with amino acids 458–607 repre-
senting the major neutralisation site) and elicits the greatest
and most long-lasting anti-HEV antibody response, being
therefore suitable both for diagnostic and seroprevalence
estimation purposes. In contrast, the amino acids 1–111 (N-
terminus) and 607–660 (C-terminus) of the ORF2 protein
and the ORF3 recombinant antigens elicit a weaker and
transient antibody response, and are consequently of limited
value in diagnosing acute HEV infection, and are not useful
for seroprevalence studies.
46,176 Importantly, all genotypes
share at least one major serologically crossreactive epitope,
despite substantial genomic variability.
62,174
Diagnosis of acute hepatitis E is made by detecting HEV-
specific IgM in acute-phase sera or by detecting a rise in anti-
HEV IgG titre between acute and convalescent serum
samples. Cases of aberrant IgM and IgG serological profiles,
including those with immunologically silent acute hepatitis
E, have been documented.
84,173 Although atypical serologi-
cal profiles from patients with proven HEV RNA viraemia
may be the expression of a modified immune response, the
insensitivity of diagnostic assays should be taken into
account when interpreting these data.
101,264,265
Molecular detection
Reverse transcription-polymerase chain reaction (RT-PCR)
assays represent the most commonly used molecular
investigation for HEV genome detection. The usage of
RT-PCR as a diagnostic tool has become feasible since the
development of the real-time PCR platforms, closed systems
that minimise the risk of contamination by the amplified
target.
The majority of HEV RT-PCR assays used for diagnosis
were developed as in-house assays by choosing different
conserved HEV genomic regions as the target for amplifica-
Hepatitis E Emerging Health Threats Journal
E Pelosi and I Clarke 2008, 1:e8
www.eht-journal.org page 8/17tion.
230,266–268 Considering the wide genetic heterogeneity
of HEV isolates, it is critical to design primers and probes that
guarantee the development of highly sensitive and broadly
reactive assays.
268
RT-PCR is a useful complementary diagnostic tool for the
diagnosis of acute HEV infection, as it can confirm cases of
hepatitis E with atypical serological profiles. RT-PCR assays
are also critically important for public health purposes when
used for detecting HEV-contaminated environmental
samples.
Prevention and control of the infection
Active immunisation
The observation that passive immune prophylaxis with
convalescent serum samples prevented hepatitis E in pri-
mates has indicated that vaccination against HEV based on
humoral immunity is feasible.
55,235,269 This has prompted
HEV immunisation studies based mainly on recombinant
proteins, because the unavailability of an efficient cell
culture system for HEV replication
270 has precluded the
development of vaccines based on inactivated or attenuated
whole-virus particles. However, other approaches, such as
DNA-based vaccines,
271,272 able to induce both cellular and
antibody response, are also under evaluation.
The ORF2 protein has been considered the best candidate
for HEV vaccine because it contains the neutralisation
epitope located between amino acids 458 and 607
56 and is
crossreactive with all mammalian HEV.
56,273 Animal studies
have shown that ORF2 recombinant proteins
274–278 elicit
neutralising antibodies and mediate protective immunity in
vaccinated primates.
277,279
One such vaccine with a 56kDa protein encompassing
amino acids 112–607
55,280 was recently evaluated in
young adults in Nepal in a phase 2, randomised, double-
blind, placebo-controlled trial.
281 The study had encoura-
ging results establishing that three doses of hepatitis E
vaccine were 95.5% effective in protecting against clinical
hepatitis E after a median of 804 days. The primary endpoint
of this study was the prevention of clinically overt HEV
infection, but the ability of the vaccine to prevent asympto-
matic infection and asymptomatic virus shedding was not
investigated.
174 Asymptomatic HEV shedding in vaccine
recipients, shown previously in primates,
280 may be relevant
in maintaining the environmental reservoir of HEV for
human infection.
174 Another aspect that this trial could not
clarify is the duration of the induced immunity. Based on
currently available data, this vaccine may be useful for
travellers to highly endemic areas and for susceptible
pregnant women,
174 particularly during outbreaks. However,
its use in children and adolescents in hepatitis E endemic
countries,
174 or in individuals with chronic liver disease,
requires further study assessing the duration of its protective
efficacy.
Protection of the environment and control of the
outbreaks
The most important measure to prevent HEV infection is the
protection of water supply from faecal contamination.
Table 1 Clinical–epidemiological characteristics of HEV infection
HEV
Genotypes
Geographical
distribution Hosts
Mode of
transmission
Epidemic versus
sporadic forms
Clinical
attack rate
Disease
severity
1
Asia
Africa
Humans
? Animals
Contamination
of water supply
Sporadic
and
epidemic
forms
Highest in
young adults
Highest in
pregnant
women and
individuals
with chronic
liver disease 2
Central America,
Africa
3
Asia,
America,
Europe,
Oceania Humans and
a variety of
animals,
particularly
swine
Food (Japan)
Sporadic and
small
outbreaks
Highest in
older males
Highest in
individuals
with chronic
liver disease
4 Asia
Food (Japan),
Environmental
contamination
by swine waste
Abbreviation: HEV, hepatitis E virus. Zoonotic strains (HEV genotype 3 and 4) cause infection both in developed and in developing countries (in italics),
such as China.
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if the source water is heavily contaminated.
223 Travellers to
highly endemic regions should strictly consume only bottled
or boiled water.
During outbreaks, it is critical to provide clean water to all
pregnant women. The isolation of individuals affected by
acute hepatitis E is not justified because person-to-person
transmission is uncommon. Infected people should refrain
from food handling and food preparation.
223
Conclusion
HEV infection has complex, and not yet completely clarified,
clinical-epidemiological characteristics, which are sum-
marised in Table 1. Two forms of infection have been
identified: hepatitis E caused by epidemic strains, affecting
mainly young adults and particularly pregnant women, and
hepatitis E caused by zoonotic strains, which mostly affect
older males.
282 These differences in sex- and age-specific
attack rates are puzzling because the route of transmission in
developed countries, apart from Japan, has not yet been
identified.
More extensive epidemiological studies are needed, not
only to assess the HEV seroprevalence in humans, but also in
several animal species. For this purpose, the development of
broadly reactive reliable antibody assays, which include
immunodominant neutralisation antigens, is critical.
Equally important is to establish which HEV genotypes
circulate among the different animal species, and their role
in human infections.
A high level of suspicion is needed in developed countries
where the increasing number of recognised cases of hepatitis
E
16,18,100–102 suggests significant underdiagnosis.
100 Aware-
ness of HEV infection should exist in immunocompromised
patients with signs of liver damage in view of the
recent finding that hepatitis E can evolve to a chronic
infection.
255,256
The results of a HEV vaccination phase 2 trial have
provided encouraging preliminary data for the prevention
of hepatitis E.
281 Data are now awaited regarding the
duration of the immune response induced by the vaccine
before routine immunisation of children can be promoted in
epidemic countries. It will also be important to establish the
vaccine efficacy among older adults and the elderly, who are
targets of overt HEV infection and in whom most cases of
chronic liver disease, a risk factor for severe hepatitis E,
concentrate.
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